Stock A251120 BIO-FD&C CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials BIO-FD&C Co.,Ltd.

Equities

A251120

KR7251120002

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 26/06/2024 am IST 		5-day change 1st Jan Change
15,800 KRW +6.04% Intraday chart for BIO-FD&C Co.,Ltd. +11.27% +11.90%
2023 Tranche Update on BIO-FD&C Co.,Ltd.'s Equity Buyback Plan announced on October 19, 2022. CI
2023 Tranche Update on BIO-FD&C Co.,Ltd.'s Equity Buyback Plan announced on October 19, 2022. CI

Valuation

Fiscal Period: December 2022 2023
Capitalization 1 1,47,827 1,22,783
Enterprise Value (EV) 1 1,10,899 83,123
P/E ratio 34.5 x 21.6 x
Yield - -
Capitalization / Revenue 9.32 x 7.87 x
EV / Revenue 6.99 x 5.33 x
EV / EBITDA 18.7 x 13.6 x
EV / FCF 3,54,50,452 x 4,39,37,505 x
FCF Yield 0% 0%
Price to Book 2.74 x 2.05 x
Nbr of stocks (in thousands) 8,696 8,696
Reference price 2 17,000 14,120
Announcement Date 01/03/23 29/02/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 5,998 8,476 8,640 11,972 15,855 15,592
EBITDA 1 826.7 3,498 3,529 3,764 5,930 6,121
EBIT 1 238.5 2,898 2,925 3,138 4,881 5,034
Operating Margin 3.98% 34.19% 33.85% 26.21% 30.78% 32.29%
Earnings before Tax (EBT) 1 269 2,993 2,881 3,293 5,443 7,152
Net income 1 394.1 2,562 2,461 2,908 4,335 5,585
Net margin 6.57% 30.22% 28.49% 24.29% 27.34% 35.82%
EPS 2 62.00 348.0 334.0 393.0 492.3 654.8
Free Cash Flow - 3,034 270.5 -4,374 3,128 1,892
FCF margin - 35.79% 3.13% -36.53% 19.73% 12.13%
FCF Conversion (EBITDA) - 86.71% 7.67% - 52.76% 30.91%
FCF Conversion (Net income) - 118.41% 10.99% - 72.16% 33.87%
Dividend per Share - - - - - -
Announcement Date 31/12/19 29/02/20 01/03/21 01/03/22 01/03/23 29/02/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 131 3,158 2,245 1,653 36,928 39,661
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - 3,034 271 -4,374 3,128 1,892
ROE (net income / shareholders' equity) - 29.5% 22% 20.5% 12.6% 10%
ROA (Net income/ Total Assets) - 13.1% 11.1% 9.64% 7.43% 5.16%
Assets 1 - 19,590 22,162 30,148 58,324 1,08,151
Book Value Per Share 2 1,164 1,353 1,686 2,141 6,211 6,873
Cash Flow per Share 2 343.0 409.0 403.0 671.0 1,338 1,393
Capex 1 1,088 257 1,875 7,017 152 1,989
Capex / Sales 18.13% 3.04% 21.7% 58.61% 0.96% 12.76%
Announcement Date 31/12/19 29/02/20 01/03/21 01/03/22 01/03/23 29/02/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
BIO-FD&C CO.,LTD. Stock BIO-FD&C Co.,Ltd.
+11.90% 9.31Cr
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+54.93% 81TCr
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.25% 65TCr
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.35% 35TCr
MERCK & CO., INC. Stock Merck & Co., Inc.
+21.81% 34TCr
ABBVIE INC. Stock AbbVie Inc.
+10.71% 30TCr
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 25TCr
ROCHE HOLDING AG Stock Roche Holding AG
+2.09% 23TCr
NOVARTIS AG Stock Novartis AG
+13.03% 22TCr
AMGEN INC. Stock Amgen Inc.
+8.82% 17TCr
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A251120 Stock
  4. Financials BIO-FD&C Co.,Ltd.